Direxion Pharma & Medical Bull 3X

FDA Accepts Viatris Meloxicam NDA, PDUFA Date Set for Dec 2026

Definium Therapeutics Completes First Patient Dosing in DT120 ODT for Major Depressive Disorder Phase 3 Clinical Trial

Axsome Therapeutics Receives FDA Approval for AUVELITY

Mizuho Raises Axsome Therapeutics Price Target to $310

Enliven Therapeutics released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.38 (forecast USD -0.4516)

Definium Therapeutics plans five Phase III studies for DT120 ODT targeting GAD and MDD

Definium Therapeutics Inc Reports Q1 EPS of $(0.71)

Viatris released FY2026 Q1 earnings on May 7 During-Market (EST), actual revenue USD 3.517 B (forecast USD 3.357 B), actual EPS USD 0.15 (forecast USD -0.8445)

Definium Therapeutics released FY2026 Q1 earnings on May 7 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7099 (forecast USD -0.4953)

Viatris Q1 2026 Revenue and Earnings Per Share Exceed Expectations

Viatris Reports Q1 2026 Earnings and Reiterates Full-Year Guidance

Oppenheimer Increases Holdings in Axsome Therapeutics

Axsome Therapeutics COO sells 4,750 shares after exercising stock options

Mizuho Securities Maintains Buy Rating on Axsome Therapeutics

Needham Raises Axsome Therapeutics Target Price to $267

FactSet lowers Axsome Therapeutics' 2026 EPS forecast

Axsome Therapeutics Reports Strong Q1 2026 Earnings, Core Product Receives FDA Approval for New Indication

Corcept Therapeutics Reports Q1 2025 Earnings

Axsome Therapeutics Reports Strong Q1 Earnings, Ovelity Receives FDA Approval

Axsome Therap released FY2026 Q1 earnings on May 4 Pre-Market (EST), actual revenue USD 191.2 M (forecast USD 190.69 M), actual EPS USD -1.2606 (forecast USD -0.8987)

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

PILL

SBIO

LABU

The US Supreme Court has rejected appeals from major drugmakers against a Medicare program that allows price negotiations for certain drugs, expected to save billions for taxpayers. The decision upholds lower court rulings and follows the 2022 Inflation Reduction Act. Drug companies argue the program violates their rights, but courts have ruled participation in Medicare is voluntary. The first round of negotiations is projected to save $6 billion for the government and reduce costs for seniors.

Yahoo Finance

NOVARTIS AG

Johnson & Johnson

Bristol Myers Squibb

Merck

AstraZeneca

ProShares Ultra Health Care ETF

ALPS Medical Breakthrough

VG Health

Direxion S&P Biotech Bull 3X

iShares US Pharma

AstraZeneca PLC

Bristol-Myers Squibb Company

Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare

IBBQ

Dana Investment Advisors Inc. reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 46.7% in Q4, owning 48,278 shares valued at $2.60 million. Other institutional investors, including Vanguard and State Street, also adjusted their stakes. Bristol Myers Squibb's stock opened at $57.04, with a market cap of $116.48 billion.

Market Beat

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

iShares Global Healthcare

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

State Street

Legal & General Group Plc

Hengrui Pharma

Bank of America

State Street® US Equity Premium Inc ETF

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Dana Investment Advisors Inc. Has $2.60 Million Holdings in Bristol Myers Squibb Company $BMY

CORT

UBS Group upgraded Corcept Therapeutics, citing increased confidence in its ovarian cancer therapy, Lifyoril. This upgrade, alongside insider share gifting, highlights Corcept's evolving profile. While optimism grows around Lifyoril's regulatory outlook, risks remain from Korlym generics and earnings volatility. Analysts project significant revenue growth, with a fair value estimate of $73.40, indicating a potential 30% upside from current prices. Investors should consider both the positive developments and ongoing challenges as they evaluate Corcept's investment narrative.

Simplywall

Corcept Therap

UBS Group AG

Teva Pharmaceutical Industries

NVIDIA

Microsoft

NVIDIA Corporation

Does Corcept Therapeutics' (CORT) UBS Upgrade and Insider Gifting Reframe Its Oncology Ambitions?

HIMS

HIMY

This week, Wall Street saw declines, particularly in technology stocks, while the S&P 500 Health Care Index gained 1.09%. Notable healthcare news includes UnitedHealth's new pharmacy pricing model set for 2027, a $15.2B licensing deal between Bristol Myers Squibb and Hengrui Pharma, and Hims & Hers Health reporting disappointing Q1 results. Additionally, concerns were raised about the potential impact of Trump's drug policy on US biopharma innovation.

businessinsider

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

Invesco S&P 500 Equal Weight Health Care ETF

Defiance Daily Target 2X Long HIMS ETF

iShares US Medical Devices

SPDR S&P Health Equip

iShares US Healthcare Providers

Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus

Organon & Co. (NYSE:OGN) has received a consensus rating of 'Reduce' from seven research firms, with three analysts recommending a sell and four a hold. The average 12-month price target is $11.40. Recent changes include Piper Sandler upgrading to 'neutral' with a price target of $14.00, while Zacks raised from 'strong sell' to 'hold'. Insider Lynette Holzbaur purchased 26,448 shares at $13.35 each. The stock opened at $13.40, with a market cap of $3.52 billion.

Organon

Piper Sandler Cos

BNP Paribas

Barclays

Lululemon

S&P 500

ROYAL BANK OF CANADA

Goldman Sachs

GS Hldg R

Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages

Tigerlily Foundation has partnered with Bristol Myers Squibb to enhance access to clinical trials for young women, particularly women of color. This collaboration aims to reduce barriers to participation and increase awareness through the ONE in a MILLION campaign, which seeks to educate one million women about clinical trials. The initiative emphasizes the importance of diversity in research to improve health equity and treatment effectiveness.

prnewswire

09:24 ETTigerlily Foundation Collaborates with Bristol Myers Squibb to Advance Clinical Trial Access and Equity

Allworth Financial LP increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 106.4% in Q4, owning 217,248 shares valued at $11.7 million. Other institutional investors also raised their holdings. Analysts have set target prices ranging from $40 to $68, with a consensus rating of 'Hold' and an average target price of $61.31. The stock opened at $56.76, with a market cap of $115.91 billion.

Morgan Stanley

HSBC Holdings Plc

HSBC

HSBC HOLDINGS

GRAIL

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

HSBC 5xShortSG241213

Bristol Myers Squibb Company $BMY Shares Acquired by Allworth Financial LP

Organon to Present New Research on Access and Value at ISPOR 2026 | OGN Stock News

StockTitan

Organon to Present New Research on Access and Value at ISPOR 2026 | OGN Stock News

XOMA

Halper Sadeh LLC is investigating XOMA, Organon & Co., and Veris Residential for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders in proposed transactions. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost. The investigations focus on XOMA's sale for $39.00 per share, Organon's sale for $14.00 per share, and Veris's sale for $19.00 per share, with the firm seeking increased consideration and disclosures on behalf of shareholders.

XOMA Royalty

Veris Residential

Ligand Pharmac-B

XOMA Corp Pref Share 8.625 Perp 12/15/21

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B

17:25 ETAre XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?

Tempus AI Inc. and Bristol Myers Squibb Co. have announced a collaboration to enhance clinical trial design using AI and real-world data across oncology and Alzheimer's programs. The initiative aims to improve drug development strategies by analyzing multimodal patient records to identify suitable patient populations and validate control groups. This partnership builds on existing efforts to address care gaps in advanced lung cancer. Tempus AI shares fell 0.96% to $45.88, while Bristol Myers Squibb shares rose 0.34% to $56.58.

benzinga_article

Tempus AI

Taiwan Semiconductor

Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts

Direxion Pharma & Medical Bull 3X(PILL.US)

Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare

Dana Investment Advisors Inc. Has $2.60 Million Holdings in Bristol Myers Squibb Company $BMY

Does Corcept Therapeutics' (CORT) UBS Upgrade and Insider Gifting Reframe Its Oncology Ambitions?

Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus

Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages